A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer Meeting Abstract
| Authors: | Baselga, J.; Morales, S. M.; Awada, A.; Blum, J. L.; Tan, A. R.; Ewertz, M.; Cortes, J.; Moy, B.; Ruddy, K. J.; Haddad, T.; Ciruelos, E. M.; Vuylsteke, P.; Ebbinghaus, S.; Im, E.; Eaton, L.; Prathiraja, K.; Gause, C.; Mauro, D.; Rugo, H. S. |
| Abstract Title: | A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer |
| Meeting Title: | 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 73 |
| Issue: | 24 Suppl. |
| Meeting Dates: | 2013 Dec 10-14 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2013-12-15 |
| Language: | English |
| ACCESSION: | WOS:000209496901053 |
| DOI: | 10.1158/0008-5472.sabcs13-p2-16-04 |
| PROVIDER: | Thomson Reuters Web of Science™ |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P2-16-04 -- Source: Wos |
